Navigation Links
Telik Announces Third Quarter 2009 Financial Results
Date:11/13/2009

ik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA®, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

                                    Telik, Inc.
                             Statements of Operations
                     (In thousands, except per share amounts)
                                    (Unaudited)

                                        Three Months Ended  Nine Months Ended
                                           September 30,      September 30,
                                           -------------      -------------
                                           2009     2008      2009      2008
                                           ----     ----      ----      ----
    Operating costs and expenses:
      Research and development            $3,416   $4,820   $10,428   $21,251
      General and administrative           2,759    2,822     8,845     8,008
      Restructuring costs                      -      199       951       199
                                             ---      ---       ---       ---
        Total operating costs and
         expenses                          6,175    7,841    2
'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
(Date:1/22/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced that it ... on Tuesday, Jan. 27, 2015, after the close of the U.S. ... with the investment community at 2 p.m. PT. Participating in the ... and chief executive officer, and other members of Amgen,s senior management ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... , , , , ... , THE WOODLANDS, Texas, July 21 ... biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, ... for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for ...
... , TOKYO, July 21 R-Tech Ueno, Ltd. ... on the new compound RK-023 that is being developed by our ... see the note below) has been completed. , ... of a patch test (open, closed, photo-patch test), single-dose study and ...
Cached Medicine Technology:Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 2Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 3Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 4R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... will receive more than $6 million in federal funding ... abuse and associated problems among U.S. military personnel, veterans, ... (NIDA), part of the National Institutes of Health, is ... grants that will examine substance abuse related to deployment ...
... University of Minnesota,s Institute for Mathematics and its Applications ... (NSF) renewal grant over the next five years. The ... the nation,s top math institutes in terms of funding. ... of Minnesota,s College of Science and Engineering, is one ...
... adenovirus to sidestep the cell,s suicide program, could go a ... in tumor cells and pave the way for a new ... Institute for Biological Studies in the Aug. 26, 2010 issue ... stress, the tumor suppressor p53 springs into action activating an ...
... Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you ... can be easily worked off at the gym, think again. ... worth of unhealthy living changes physiology, making piled-on fat even ... have later long-term effects," said study co-author Dr. Torbjorn Lindstrom, ...
... at Mayo Clinic discovered several years ago that laboratory samples ... to help them find new treatments for this lethal disease ... became evident that the situation in their lab was common ... that were supposed to originate from patients with this rare ...
... Gardner HealthDay Reporter , TUESDAY, Aug. 24 ... to Monday,s decision by a U.S. judge to ... funds. The temporary injunction, which basically blindsided the ... to the pre-2001 days. That was when then-President Bush ...
Cached Medicine News:Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 3Health News:University of Minnesota math institute receives $20.5 million NSF grant 2Health News:Use the common cold virus to target and disrupt cancer cells? 2Health News:Use the common cold virus to target and disrupt cancer cells? 3Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Mayo researchers develop new laboratory cell lines to study treatment for ATC 2Health News:Mayo researchers develop new laboratory cell lines to study treatment for ATC 3Health News:Scientists Dismayed by Stem Cell Research Ruling 2Health News:Scientists Dismayed by Stem Cell Research Ruling 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: